Trial Profile
A Phase II Clinical And Biologic Study Of The Combination Of Low Dose Interferon-Alpha And Thalidomide (NSC 66847) For Patients With Relapsed Or Refractory Low-Grade Follicular Lymphoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2013
Price :
$35
*
At a glance
- Drugs Interferon alpha (Primary) ; Thalidomide (Primary)
- Indications Follicular lymphoma
- Focus Biomarker; Therapeutic Use
- 11 Sep 2005 New trial record.